Opinion|Videos|November 1, 2024
Clinical Impact of ALK Inhibitor Data: Efficacy, Brain Metastases, and CNS Management Strategies
Panelists discuss how recent data influence treatment choices for ALK-positive NSCLC patients, highlighting specific patient factors that guide decisions and potential concerns regarding the use of lorlatinib as first-line therapy.
Advertisement
- Dr Gadgeel: How do these data impact your treatment choice for your patients?
- What specific patient factors would influence your decision between treatment options? What concerns might prevent you from choosing lorlatinib as a first-line treatment?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
3
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
4
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
5































